Drive patient access to oncology drugs with exclusive insights from key stakeholders and thought-leaders from all over Europe
Create compelling value stories by the learning what payers, regulators and patients are thinking
Discuss market access hurdles and incremental innovation with payers to find collaborative solutions to slow patient access
Understand the meaning of value to all oncology stakeholders with key insights from payers, regulators, patients and senior pharma executives
Prepare for future opportunities and pitfalls as risk-sharing agreements, new endpoint guidelines and value-based pricing change the reimbursement landscape
Gain insider perspective from NICE & NHS (UK), AIFA (Italy), IQWIG & DAK (Germany), AETS (Spain), Sante Suisse(Switzerland) and NFZ (Poland) for a true understanding of pan-European trends and how different countries are dealing with austerity
"Presentations were great and very interesting with good speakers"
Vincent Theas, Business Intelligence Manager, Eisai
The keynote speeches, payer presentations and patient perspectives last year answered many questions but bigger challenges have risen in the past year.
Hear how:
Value-based pricing, pay-for-performance and the German Healthcare Reforms (AMNOG) will affect access for your oncology drugs
You can successfully integrate clinical and market access teams for more effective and impactful value propositions
Patient groups and payers are becoming increasingly involved in the development of innovative drugs to improve the speed of approval and allow for more collaborative payer agreements
Learn how to manage the present and prepare for the future…
With a great mix of top level pharma speakers, master strategists, HTA bodies, payers and patients, learn how to deal with your most current challenges AND discover the next steps for you company.
Hear one of the hot topics from last year’s event
Evolve your oncology marketing plan for a more targeted approach